coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
emerg
wuhan
china
decemb
spread
rapidli
across
world
due
high
transmiss
pathogen
munster
et
al
zhu
et
al
distinct
clade
beta
coronavirus
encompass
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
although
case
diseas
caus
pathogen
coronavirus
mild
su
et
al
sarscov
merscov
outbreak
respect
demonstr
high
lethal
schoeman
field
bear
resembl
genom
sequenc
sarscov
chan
et
al
howev
present
lower
case
fatal
rate
higher
infecti
sar
mortal
rate
approxim
sar
patient
often
exhibit
mild
symptom
fever
cough
myalgia
fatigu
gener
good
prognosi
howev
larg
proport
case
rapidli
progress
sever
type
especi
among
older
men
underli
diseas
chen
et
al
huang
et
al
liu
et
al
wang
et
al
sever
case
includ
dyspnea
shock
organ
dysfunct
acut
respiratori
distress
syndrom
ard
wang
et
al
xu
et
al
yang
et
al
yao
et
al
acut
cardiac
injuri
strabelli
uip
wang
et
al
yao
et
al
zhou
et
al
acut
kidney
injuri
pan
et
al
wang
et
al
yao
et
al
acut
liver
injuri
xu
et
al
yao
et
al
zhang
et
al
neurolog
injuri
mao
et
al
wu
et
al
gastrointestin
injuri
yao
et
al
immun
injuri
guan
et
al
qin
et
al
wang
et
al
xu
et
al
yao
et
al
liu
et
al
zheng
et
al
coagul
impair
tang
et
al
even
death
wang
et
al
fig
addit
pandem
great
impact
psycholog
stress
mental
health
worldwid
bao
et
al
kang
et
al
li
et
al
pfefferbaum
north
shi
et
al
present
pathogenesi
etiolog
remain
unclear
target
therapi
patient
empir
administ
symptomat
treatment
organ
support
serious
ill
given
pandem
spread
result
global
econom
loss
develop
altern
agent
contain
imper
review
summar
potenti
therapeut
candid
http
receiv
april
receiv
revis
form
april
accept
april
develop
base
clinic
trial
describ
potenti
mechan
action
fig
fig
remdesivir
nucleotid
prodrug
origin
develop
control
ebola
viru
subsequ
demonstr
efficaci
inhibit
coronavirus
sarscov
merscov
vitro
sheahan
et
al
present
antivir
activ
interf
rnadepend
rna
polymeras
therebi
attack
viru
abil
replic
bodi
fig
agostini
et
al
recent
studi
indic
remdesivir
effici
protect
human
cell
line
infect
treatment
intraven
remdesivir
success
improv
clinic
state
first
us
patient
holshu
et
al
remdesivir
test
sever
clinic
trial
design
evalu
efficaci
safeti
treatment
notabl
gilead
scienc
announc
result
recent
clinic
studi
efficaci
remdesivir
grein
et
al
report
patient
infect
sever
track
patient
critic
ill
patient
requir
mechan
ventil
patient
reli
extracorpor
membran
oxygen
ecmo
median
followup
day
patient
present
improv
oxygensupport
class
patient
sever
ill
patient
show
improv
clinic
condit
patient
stop
receiv
invas
mechan
ventil
patient
stop
receiv
ecmo
treatment
respect
treatment
remdesivir
limit
mortal
rate
serious
ill
patient
need
invas
ventil
need
gener
efficaci
remdesivir
reflect
studi
hope
howev
sampl
size
studi
quit
small
definit
effect
remdesivir
treatment
need
verifi
tabl
lopinavirritonavir
lpvr
coformul
human
immunodefici
viru
hiv
specif
proteas
inhibitor
serv
firstlin
therapi
hiv
barragan
podzamcz
concomit
use
ritonavir
could
increas
plasma
halflif
lopinavir
cytochrom
inhibit
liver
sar
outbreak
lpvr
report
vitro
inhibitori
activ
sarscov
chu
et
al
combin
therapi
lpvr
ribavirin
provid
favor
result
treat
patient
sar
fig
chu
et
al
tripl
combin
therapi
lpvr
ribavirin
shown
clinic
effect
mer
kim
et
al
notwithstand
recent
openlabel
random
studi
patient
wuhan
show
lpvr
monotherapi
produc
therapeut
benefit
patient
compar
standard
support
care
might
caus
higher
throat
viral
load
lpvr
group
concurr
pharmacolog
intervent
late
treatment
initi
tabl
enrol
patient
critic
ill
lpvr
treatment
might
start
rel
late
howev
anoth
retrospect
cohort
studi
combin
therapi
lpvr
arbidol
associ
improv
pulmonari
comput
tomographi
imag
infectioninduc
impair
multipl
organ
function
impair
multipl
organ
function
infect
includ
acut
respiratori
distress
syndrom
ard
acut
cardiac
injuri
acut
kidney
injuri
acut
liver
injuri
neurolog
injuri
gastrointestin
injuri
immun
system
injuri
coagul
impair
abbrevi
alt
alanin
transaminas
aptt
activ
partial
thromboplastin
time
ard
acut
respiratori
distress
syndrom
ast
aspart
aminotransferas
ckmb
creatin
kinas
myocardi
band
cn
central
nervou
system
fdp
fibrinogen
degrad
product
hladr
human
leukocyt
antigen
dr
inr
intern
normal
ratio
ldh
lactat
dehydrogenas
myo
myoglobin
nk
natur
killer
cell
ntprobnp
n
termin
probtyp
natriuret
peptid
oxygen
index
pn
peripher
nervou
system
pt
prothrombin
time
raa
reninangiotensinaldosteron
system
sever
acut
respiratori
syndrom
coronaviru
tbil
total
bilirubin
th
helper
cell
tni
troponin
collect
combin
therapi
lpvr
antivir
agent
earli
stage
infect
might
hold
promis
treat
favipiravir
also
known
origin
develop
approv
influenza
viru
infect
epidem
japan
broad
spectrum
antivir
activ
furuta
et
al
enter
cell
favipiravir
undergo
phosphoryl
convert
activ
phosphoryl
form
favipinavirrtp
potent
inhibit
viral
rna
polymeras
therebi
interf
viral
genom
replic
fig
furuta
et
al
favipiravir
demonstr
efficaci
inhibit
wide
rang
virus
includ
resist
influenza
virus
rna
virus
arenavirus
bunyavirus
filovirus
delang
et
al
previou
studi
show
favipiravir
efficaci
ebola
viru
rodent
model
oestereich
et
al
smither
et
al
effect
human
unproven
sissoko
et
al
favipiravir
appear
effect
two
clinic
trial
involv
total
patient
conduct
wuhan
shenzhen
press
confer
march
xinmin
zhang
offici
china
scienc
technolog
ministri
state
favipiravir
appear
effect
hackett
preliminari
clinic
data
patient
third
peopl
hospit
shenzhen
suggest
favipiravir
exert
antivir
effect
potent
lpvr
overt
advers
reaction
hypothet
replic
cycl
possibl
target
drug
bind
receptor
surfac
cell
use
spike
protein
subsequ
trigger
endocytosi
releas
viral
nucleocapsid
cytoplasm
encapsid
positivestrand
genom
rna
grna
serv
templat
translat
polypeptid
chain
cleav
nonstructur
protein
includ
rnadepend
rna
polymeras
singl
neg
strand
rna
grna
synthes
grna
templat
employ
replic
copi
viral
rna
subgenom
rna
sgrna
synthes
discontinu
transcript
grna
templat
encod
viral
structur
accessari
protein
subsequ
assembl
newli
synthes
viral
rna
form
new
virion
nascent
virion
transport
secretori
vesicl
plasma
membran
releas
exocytosi
convalesc
plasma
jak
inhibitor
baricitinib
could
dampen
bind
spike
protein
surfac
express
cell
surfac
lopinavirritonavir
favipiravir
inhibit
proteolysi
polypeptid
chain
remdesivir
inhibit
rnadepend
rna
polymeras
could
inhibit
replic
zinc
might
inhibit
replic
vitamin
might
induc
antimicrobi
peptid
reduc
replic
ivermectin
could
effect
block
growth
baricitinib
could
interrupt
passag
enter
cell
inhibit
endocytosi
cq
hcq
inhibit
viruscel
fusion
process
lhqw
ifn
could
block
process
viru
replic
rna
transcript
protein
translat
posttransl
modif
abbrevi
adaptorassoci
kinas
cq
chloroquin
er
endoplasm
reticulum
hcq
hydroxychloroquin
sulfat
ifn
interferon
ino
inhal
nitric
oxid
jak
janu
kinas
lhqw
lianhua
qingwen
recombin
human
angiotensinconvert
enzym
sever
acut
respiratori
syndrom
coronaviru
third
peopl
clinic
trial
wuhan
show
base
convent
therapi
favipiravir
demonstr
higher
efficaci
arbidol
term
recoveri
rate
durat
symptom
attenu
patient
moder
infect
taken
togeth
clinic
result
favipiravir
favor
tabl
howev
studi
favipiravir
monotherapi
use
larg
sampl
size
need
research
emori
univers
univers
north
carolina
vanderbilt
univers
medic
center
test
new
drug
vitro
efficaci
laboratori
result
encourag
sheahan
et
al
base
oral
bioavail
ribonucleotid
analog
design
optim
oral
bioavail
improv
drug
uptak
human
nonhuman
primat
fig
varieti
antivir
activ
numer
causal
agent
deleteri
viral
infecti
diseas
includ
influenza
chikungunya
ebola
venezuelan
equin
enceph
coronavirusassoci
diseas
agostini
et
al
painter
et
al
reynard
et
al
toot
et
al
ribonucleotid
analog
share
similar
mechan
action
remdesivir
exert
antivir
effect
mimick
ribonucleotid
therebi
mistakenli
incorpor
viral
rna
lead
lethal
mutagenesi
virion
rna
synthesi
inhibit
rnadepend
rna
polymeras
encod
viru
viral
replic
fig
sheahan
et
al
studi
suggest
robustli
block
replic
sarscov
merscov
newli
emerg
cell
assay
demonstr
prophylact
therapeut
effect
murin
model
sar
mer
show
diminish
viral
lung
titer
attenu
weight
loss
amelior
lung
damag
improv
pulmonari
function
depend
administ
dosag
treatment
initi
time
compar
remdesivir
appear
favor
conveni
oral
administr
remdesivir
must
reli
intraven
administr
train
specialist
importantli
show
activ
antivir
activ
fig
hypothet
mechan
infectioninduc
cytokin
storm
antivir
immun
possibl
therapeut
target
patient
infect
cytokin
storm
might
start
inflammatori
cytokin
secret
lung
tissu
pulmonari
blood
vessel
virusinfect
alveolar
epitheli
cell
pulmonari
vascular
endotheli
cell
alveolar
macrophag
multinucl
giant
cell
infiltr
immun
cell
mainli
serv
limit
replic
spread
viru
induc
downstream
immun
respons
via
blood
circul
follow
recruit
activ
primari
cytokin
system
immun
cell
neutrophil
dc
nk
cell
cell
cell
cell
cell
cell
etc
secret
inflammatori
cytokin
promot
cascad
inflammatori
process
elimin
viru
virusinfect
cell
vitamin
c
might
inhibit
allevi
ill
decreas
inflammatori
cytokin
stimul
ifn
product
support
lymphocyt
prolifer
boost
phagocyt
capabl
neutrophil
monocyt
macrophag
protect
lung
barrier
function
reduc
lung
vascular
injuri
increas
ifn
secret
alveolar
dc
nk
cell
cell
ifn
could
enhanc
nk
cell
cytotox
enhanc
express
major
histocompat
complex
protein
promot
product
ifn
prolifer
nk
cell
bevacizumab
could
reduc
vascular
permeabl
vaccin
pittcovacc
could
induc
protect
antivir
immun
memori
msc
could
decreas
proinflammatori
cytokin
promot
regener
secret
multipl
paracrin
factor
antiinflammatori
cytokin
enlarg
proport
treg
cell
ino
could
allevi
pulmonari
hypertens
select
pulmonari
vasodil
corticosteroid
lhqw
xuebij
ivig
tocilizumab
sarilumab
baricitinib
vitamin
cq
hcq
could
also
reduc
inflamm
heparin
block
thrombu
format
abbrevi
type
alveolar
epitheli
cell
type
alveolar
epitheli
cell
cq
chloroquin
dc
dendrit
cell
gcsf
granulocytecoloni
stimul
factor
hcq
hydroxychloroquin
sulfat
interferon
gamma
il
interleukin
ino
inhal
nitric
oxid
interferoninduc
ivig
intraven
gamma
globulin
lhqw
lianhua
qingwen
monocyt
chemotact
protein
macrophag
inflammatori
monocytemacrophag
msc
mesenchym
stem
cell
nk
natur
killer
cell
sever
acut
respiratori
syndrom
coronaviru
th
helper
cell
tumor
necrosi
factor
alpha
treg
regulatori
cell
remdesivirresist
virus
accord
data
present
studi
signific
import
appear
effect
sarscov
merscov
also
coronaviru
speci
indic
potenti
efficaci
emerg
coronavirus
futur
us
food
drug
administr
fda
approv
investig
new
drug
applic
clinic
studi
human
expect
start
soon
possibl
tabl
biospac
convalesc
plasma
collect
donor
surviv
infecti
diseas
produc
protect
antibodi
consid
provid
great
degre
protect
recipi
affect
emerg
viru
dodd
convalesc
plasma
success
employ
treat
numer
infecti
diseas
includ
epidem
influenza
viru
pandem
merscov
epidem
dodd
hung
et
al
mairjenkin
et
al
modern
medicin
specif
effect
treatment
absenc
specif
antivir
agent
vaccin
clinic
trial
conduct
aim
investig
efficaci
convalesc
plasma
treat
recent
publish
studi
chines
research
confirm
efficaci
convalesc
plasma
control
tabl
roback
guarner
report
suggest
patient
show
sign
improv
approxim
week
convalesc
plasma
transfus
anoth
clinic
studi
involv
critic
ill
patient
infect
differ
hospit
wuhan
suggest
hightit
convalesc
plasma
transfus
effect
neutral
lead
imped
inflammatori
respons
improv
symptom
condit
without
sever
advers
event
patient
receiv
convalesc
plasma
transfus
show
improv
clinic
outcom
cure
discharg
hospit
given
clinic
effect
convalesc
plasma
fda
grant
clinic
permiss
appli
convalesc
plasma
treatment
critic
ill
patient
fda
angiotensinconvert
enzym
serv
neg
regul
renin
angiotensin
system
ra
wide
distribut
among
lung
tissu
mani
extrapulmonari
tissu
includ
brain
heart
liver
kidney
endothelium
intestin
fig
crackow
et
al
ding
et
al
ham
et
al
alveolar
epitheli
type
cell
possess
abund
receptor
unfortun
also
function
receptor
sarscov
li
et
al
spike
protein
sarscov
bind
host
receptor
enter
target
cell
fig
critic
show
higher
affin
sarscov
wrapp
et
al
moreov
protein
contain
site
recogn
activ
host
enzym
call
furin
highli
express
lung
coutard
et
al
find
might
provid
strong
evid
high
pathogen
due
pivot
role
wide
distribut
entri
replic
virus
block
protein
bind
might
offer
protect
infect
fig
studi
use
murin
model
sar
show
sarscov
protein
bind
led
ra
downregul
consequ
contribut
sever
lung
injuri
therefor
recombin
human
might
protect
host
lung
infect
enhanc
level
neutral
protein
surfac
clinic
evid
demonstr
safeti
applic
haschk
et
al
khan
et
al
recent
vitro
studi
demonstr
fusion
protein
fc
fragment
show
high
affin
bind
receptorbind
domain
potent
neutral
addit
find
newli
onlin
publish
report
cell
strongli
support
potenti
efficaci
infect
monteil
et
al
studi
show
clinicalgrad
human
recombin
solubl
display
potent
inhibitori
activ
cell
cultur
engin
replica
human
blood
vessel
kidney
dosedepend
manner
research
found
infect
cell
coincub
rather
mous
recombin
solubl
demonstr
drop
activ
infect
cell
organoid
level
administr
significantli
block
infect
engin
human
blood
vessel
kidney
without
observ
toxic
howev
note
studi
focus
earli
stage
infect
still
unclear
whether
play
role
later
infect
process
taken
togeth
like
potenti
cur
effect
clinic
trial
underway
investig
efficaci
treatment
tabl
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
wide
use
treat
cardiovascular
diseas
studi
shown
aceisarb
upregul
express
ferrario
et
al
ishiyama
et
al
karram
et
al
might
correl
suscept
howev
evid
shown
ra
activ
decreas
express
contribut
patholog
process
lung
injuri
sarscov
infect
serum
angiotensin
ii
level
markedli
elev
exhibit
linear
posit
correl
viral
load
lung
injuri
liu
et
al
consequ
effect
aceisarb
lungspecif
express
remain
unknown
aceisarb
might
dual
role
one
hand
elev
level
might
increas
suscept
activ
ra
deregul
might
amelior
acut
lung
injuri
heart
injuri
renal
damag
induc
howev
definit
evid
whether
take
aceisarb
benefici
harm
infect
patient
chloroquin
cq
drug
wide
use
treat
malari
autoimmun
diseas
also
confer
consider
broadspectrum
antivir
effect
even
sarscov
tabl
keyaert
et
al
savarino
et
al
yan
et
al
recent
studi
demonstr
cq
activ
vitro
fig
subsequ
letter
bioscienc
confirm
cq
efficaci
treat
pneumonia
numer
relat
clinic
trial
cq
therapi
result
improv
pulmonari
lesion
shorten
diseas
cours
good
outcom
tabl
given
effici
display
cq
clinic
practic
cq
includ
guidelin
diagnosi
treatment
edit
issu
nation
commiss
peopl
republ
china
nhpfc
hydroxychloroquin
sulfat
hcq
share
similar
chemic
structur
mechan
action
cq
lower
ocular
toxic
lim
et
al
proven
efficaci
contain
vitro
cq
hcq
exert
antivir
function
variou
mechan
cq
shown
interfer
glycosyl
process
host
cell
therebi
inhibit
effici
bind
protein
turn
disrupt
viruscel
fusion
process
fig
savarino
et
al
cq
increas
ph
acid
cellular
organel
requir
viru
entri
host
cell
savarino
et
al
addit
direct
antivir
activ
cq
hcq
attenu
major
cytokin
storm
overreact
immun
system
caus
inflammatori
storm
decreas
cytokin
product
interleukin
il
tumor
necrosi
factor
tnf
etc
fig
van
den
born
et
al
notabl
high
cytokin
concentr
observ
serious
ill
patient
indic
overreact
immun
respons
exacerb
therefor
immunemodul
activ
hcq
might
partial
account
effici
control
infect
cq
hcq
therefor
promis
drug
choic
largescal
use
due
low
cost
wide
avail
potenti
efficaci
treat
cq
hcq
need
administ
caution
treat
infect
prevent
toxic
recent
openlabel
studi
franc
show
hcq
treatment
significantli
associ
viral
load
reductiondisappear
patient
effect
reinforc
azithromycin
gautret
et
al
although
studi
openlabel
studi
use
small
sampl
size
combin
hcq
azithromycin
could
promis
candid
patient
contrast
multin
network
cohort
selfcontrol
case
seri
studi
demonstr
shortterm
hcq
treatment
safe
lane
et
al
howev
combin
hcq
azithromycin
may
induc
increas
risk
day
cardiovascular
mortal
chest
painangina
heart
failur
lane
et
al
therefor
must
pay
attent
combin
therapi
manag
patient
tocilizumab
tcz
sarilumab
monoclon
antibodi
receptor
employ
treat
rheumatoid
arthriti
nishimoto
et
al
raimondo
et
al
tcz
sarilumab
effici
inhibit
membranebound
solubl
fig
raimondo
et
al
sakka
tcz
approv
fda
treat
cytokin
releas
syndrom
mark
excess
cytokin
product
consequ
rapid
multiorgan
damag
lung
kidney
heart
shimabukurovornhagen
et
al
diseas
sever
depend
increas
proinflammatori
factor
granulocytecoloni
stimul
factor
protein
monocyt
chemoattract
protein
macrophag
inflammatori
alpha
ruan
et
al
zhou
et
al
suggest
cytokin
storm
involv
develop
one
key
cytokin
involv
immun
system
perturb
mehta
et
al
receptor
antagonist
tcz
sarilumab
therefor
hypothes
exert
suppress
effect
exuber
dysfunct
systemat
inflamm
patient
infect
improv
patient
condit
three
clinic
trial
tcz
approv
nation
health
famili
plan
commiss
china
approv
treatment
tcz
patient
elev
level
tabl
nhpfc
encourag
result
seen
itali
three
serious
ill
patient
administ
tcz
show
sign
improv
italian
ansa
news
agenc
accord
announc
regeneron
pharmaceut
sanofi
march
phase
clinic
trial
us
sarilumab
conduct
assess
therapeut
effect
patient
sever
infect
tabl
regeneron
bevacizumab
monoclon
antivascular
endotheli
growth
factor
vegf
antibodi
compet
vegf
receptor
surfac
endotheli
cell
vegf
bind
therebi
inhibit
effect
caus
bind
vegf
receptor
endotheli
cell
prolifer
neovascular
fig
ferrara
et
al
vegf
produc
variou
inflammatori
epitheli
cell
potent
vascular
permeabl
induc
dvorak
et
al
previou
report
shown
plasma
vegf
level
markedli
increas
patient
ard
thickett
et
al
given
causal
link
ard
increas
vascular
permeabl
pulmonari
edema
fanelli
ranieri
bevacizumab
might
potenti
antiard
therapeut
approach
ard
common
complic
sever
case
fig
bevacizumab
therefor
like
promis
therapi
tabl
baricitinib
highli
select
janu
kinas
jak
inhibitor
approv
treat
rheumatoid
arthriti
alsalama
scott
jakdepend
pathway
respons
produc
varieti
cytokin
involv
pathogenesi
progress
process
character
elev
level
inflammatori
factor
eg
oshea
pleng
baricitinib
also
serv
inhibitor
adaptorassoci
kinas
member
numbassoci
kinas
famili
play
central
role
regul
endocytosi
viru
invad
host
cell
fig
richardson
et
al
therefor
baricitinib
might
exert
benefici
effect
pneumonia
imped
overexuber
immun
respons
hijack
cytokin
signal
pathway
also
prevent
enter
host
cell
howev
blockag
jakdepend
pathway
baricitinib
also
inhibit
product
interferon
ifn
oshea
pleng
might
antivir
activ
fig
et
al
baricitinib
treatment
therefor
doubleedg
sword
tabl
choos
appropri
time
administ
baricitinib
vital
import
sever
ill
patient
abnorm
biomark
cautiou
baricitinib
treatment
might
yield
clinic
benefici
effect
mesenchym
stem
cell
msc
multipot
cell
isol
divers
mesenchym
tissu
eg
bone
marrow
umbil
cord
adipos
tissu
lv
et
al
virtu
low
immunogen
chamberlain
et
al
proven
safeti
zheng
et
al
repar
immunomodulatori
properti
galipeau
mei
et
al
msc
attract
therapeut
candid
treat
wide
rang
diseas
eg
graftversushost
diseas
le
blanc
et
al
sepsi
ard
fig
asmussen
et
al
krasnodembskaya
et
al
larg
bodi
preclin
data
demonstr
efficaci
msc
treat
ard
manifest
reduc
pulmonari
edema
decreas
plasma
concentr
proinflammatori
cytokin
reduc
mortal
rate
chimenti
et
al
devaney
et
al
xu
et
al
although
fulli
understood
mechan
msc
exert
protect
effect
includ
direct
regen
abil
secret
multipl
paracrin
factor
includ
antibacteri
peptid
antiinflammatori
cytokin
gupta
et
al
gupta
et
al
anoth
attract
properti
msc
immun
respons
modul
aggarw
pitteng
msc
shown
enlarg
proport
regulatori
cell
decreas
proinflammatori
factor
fig
li
et
al
prevosto
et
al
msc
show
posit
efficaci
recent
studi
patient
treatment
allogen
msc
transplant
beij
youan
hospit
show
significantli
improv
function
outcom
without
obviou
advers
effect
patient
tabl
zikuan
leng
et
al
adopt
msc
transfer
might
therefor
valuabl
treatment
option
nitric
oxid
key
endogen
molecul
implic
varieti
physiolog
patholog
process
includ
smooth
muscl
relax
immun
respons
antimicrobi
activ
saura
et
al
schmidt
walter
due
potent
select
pulmonari
vasodil
ino
extens
appli
treat
pulmonari
hypertens
ard
respiratori
diseas
rel
good
safeti
profil
fig
griffith
evan
pepkezaba
et
al
note
previous
publish
invitro
studi
indic
possess
inhibitori
effect
sarscov
replic
fig
et
al
keyaert
et
al
moreov
smallsampl
clinic
studi
test
efficaci
ino
treatment
sar
show
sever
infect
patient
receiv
ino
therapi
present
improv
arteri
oxygen
reduct
need
ventil
support
chen
et
al
view
high
incid
pulmonari
complic
infect
patient
ino
therapi
may
serv
promis
candid
treat
sever
case
via
allevi
lung
damag
current
relat
phase
clinic
trial
test
ino
underway
infect
patient
complic
ard
tradit
chines
medicin
tcm
uniqu
wellestablish
system
medicin
wide
employ
thousand
year
prevent
treat
numer
diseas
china
battl
stop
epidem
situat
integr
tradit
chines
western
medicin
uniqu
scheme
china
approxim
chines
patient
underw
tcm
treatment
report
xunanp
vice
minist
scienc
technolog
china
china
state
council
clinic
practic
sever
kind
tcm
demonstr
benefici
effect
treat
patient
pneumonia
lianhua
qingwen
lhqw
broadspectrum
antivir
effect
host
influenza
virus
influenza
hpai
virus
inhibit
viral
propag
regul
immun
function
fig
ding
et
al
dong
et
al
lhqw
commonli
use
treat
viral
influenza
clinic
play
key
role
control
sarscov
outbreak
recent
lhqw
report
inhibitori
activ
antiinflammatori
effect
vitro
tabl
runfeng
et
al
xuebij
whose
chemic
composit
includ
safflow
yellow
paginin
ferul
acid
salvianol
acid
b
function
endotoxin
antagonist
antiinflammatori
agent
anticoagul
et
al
sun
et
al
xu
et
al
zhang
et
al
wide
use
china
therapi
sepsi
fig
chen
et
al
clinic
trial
show
inject
xuebij
improv
symptom
sever
pneumonia
given
cytokin
storm
sever
infect
administ
xuebij
could
turn
critic
ill
case
mild
one
attenu
overactiv
immun
respons
prevent
progress
patholog
deterior
two
clinic
trial
aim
test
efficaci
safeti
xuebij
inject
regist
chines
clinic
trial
registri
tabl
addit
lhqw
xuebij
chines
clinic
guidelin
pneumonia
treatment
includ
jinhua
qinggan
granul
shufeng
jiedu
capsul
lung
cleans
detoxifi
decoct
given
potenti
efficaci
advers
effect
clinic
treat
infect
nhpfc
ifn
larg
famili
numer
type
speci
one
type
speci
liu
parkin
cohen
type
ifn
demonstr
inhibitori
effect
wide
rang
virus
includ
sarscov
fig
minagawa
et
al
sperber
hayden
et
al
tan
et
al
encount
virus
host
cell
form
releas
ifn
protect
origin
adjac
cell
attack
antivir
state
produc
effect
sever
mean
inhibit
viral
rna
transcript
protein
translat
posttransl
modif
fig
fig
de
andrea
et
al
date
clinic
effect
ifn
intervent
infect
ambigu
previou
evid
confirm
ifn
efficaci
inhibit
sarscov
cinatl
et
al
sainz
et
al
show
vitro
inhibitori
effect
sarscov
concentr
iuml
et
al
interestingli
recombin
human
within
safe
dose
rang
exhibit
potent
activ
sarscov
hensley
et
al
regist
agent
chronic
hepat
c
report
protect
type
pneumocyt
sar
coronaviru
infect
macaqu
haagman
et
al
combin
treatment
ribavirin
shown
antivir
effect
merscov
falzarano
et
al
addit
antivir
activ
ifn
show
immunomodulatori
capabl
type
interferon
enhanc
natur
killer
nk
cell
cytotox
enhanc
express
major
histocompat
complex
protein
well
promot
ifn
product
prolifer
nk
cell
macrophag
de
andrea
et
al
goodbourn
et
al
sen
conjunct
corticosteroid
shown
improv
oxygen
satur
facilit
rapid
resolut
radiograph
lung
abnorm
sar
infect
loutfi
et
al
studi
use
merscov
infect
mous
model
indic
earli
applic
exogen
facilit
viru
clearanc
protect
fatal
lung
infect
delay
administr
tend
elev
damag
proinflammatori
cytokin
respons
led
deleteri
outcom
channappanavar
et
al
given
inconclus
effect
ifn
treat
viral
infecti
diseas
ifn
combin
therapi
prudent
employ
infect
tabl
intraven
gamma
globulin
ivig
purifi
igg
product
prepar
pool
human
plasma
wide
use
treat
numer
inflammationrel
diseas
includ
heart
failur
adult
respiratori
distress
syndrom
vascul
joll
et
al
ivig
demonstr
passiv
immun
antiinflammatori
effect
suppli
idiotyp
antibodi
kaveri
et
al
bind
fc
receptor
fehr
et
al
suppress
pathogen
cytokin
andersson
andersson
andersson
et
al
prevent
format
membranolyt
attack
complex
lutz
et
al
modul
tcell
function
fig
marchaloni
et
al
transchromosom
bovineproduc
human
polyclon
immunoglobulin
g
antibodi
inhibit
merscov
murin
model
vitro
assay
luke
et
al
due
scarciti
humanderiv
igg
product
convalesc
plasma
therapeut
immunoglobulin
might
provid
insight
treatment
tabl
howev
ivig
care
administ
given
numer
advers
effect
eg
myalgia
fever
renal
failur
achiron
bertorini
et
al
wajanaponsan
cheng
venou
thromboembol
hoffmann
enk
thromboembol
found
third
patient
sar
underw
ivig
treatment
sar
outbreak
singapor
lew
et
al
nk
cell
small
subset
peripher
white
blood
cell
serv
essenti
part
innat
immun
respons
nk
cell
elicit
rapid
robust
protect
effect
defens
viral
infect
direct
cytotox
immunomodulatori
capabl
fig
vivier
et
al
recogn
infect
host
cell
nk
cell
trigger
target
cell
apoptosi
perforinand
granzym
bmediat
pathway
secret
multipl
cytokin
involv
regul
innat
adapt
immun
respons
facilit
viral
clearanc
iannello
et
al
nk
cellbas
immunotherapi
long
investig
treat
malign
albeit
limit
clinic
practic
due
difficulti
obtain
suffici
cell
number
adopt
transfer
lee
recent
investig
allogen
nk
cell
therapi
deriv
placent
hematopoiet
stem
cell
pass
investig
new
drug
applic
approv
fda
celular
nk
cell
product
harbor
potenti
inhibit
viral
infect
direct
kill
infect
host
cell
indirect
induc
immun
respons
howev
exist
controversi
whether
elicit
strong
inflammatori
respons
favor
detriment
patient
infect
sever
efficaci
safeti
nk
cell
therapi
requir
test
ongo
relat
clinic
trial
due
excel
antiinflammatori
antifibrot
properti
j
zhang
et
al
brain
behavior
immun
xxx
xxxx
xxxxxx
abil
suppress
collagen
deposit
corticosteroid
frequent
use
treat
ard
sepsi
fig
heme
et
al
rhen
cidlowski
thompson
despit
long
histori
administ
corticosteroid
therapeut
effect
safeti
remain
controversi
sever
clinic
trial
metaanalys
indic
corticosteroid
associ
increas
mortal
tendenc
requir
mechan
ventil
therapi
rel
longer
hospit
sar
mer
infect
arabi
et
al
han
et
al
stockman
et
al
advers
event
partli
due
suppress
normal
host
immun
respons
imped
viral
clearanc
numer
studi
howev
demonstr
corticosteroid
benefici
effect
physiolog
outcom
virusassoci
respiratori
diseas
support
proper
applic
corticosteroid
case
especi
critic
case
siemieniuk
et
al
retrospect
studi
patient
sar
show
corticosteroid
reduc
case
fatal
rate
shorten
hospit
stay
chen
et
al
accur
conclus
regard
therapeut
effect
corticosteroid
treat
therefor
drawn
tabl
high
corticosteroid
dose
close
associ
advers
event
secondari
infect
delay
viral
clearanc
emerg
viral
resist
accord
guidelin
diagnosi
treatment
edit
china
nhpfc
howev
prudent
lowtomoder
dose
corticosteroid
could
yield
potenti
therapeut
benefit
subset
serious
ill
patient
pneumonia
recommend
line
interim
clinic
manag
guidanc
releas
world
health
organ
advis
routin
administ
corticosteroid
except
clinic
indic
exacerb
chronic
obstruct
pulmonari
diseas
septic
shock
tang
et
al
investig
effect
anticoagul
heparin
patient
sever
ddimer
prothrombin
time
age
posit
platelet
count
neg
correl
mortal
differ
mortal
heparin
user
nonus
howev
mortal
heparin
user
lower
nonus
studi
suggest
anticoagul
therapi
heparin
appear
associ
better
prognosi
sever
patient
tang
et
al
interestingli
patient
sever
pneumonia
higher
platelet
count
induc
former
markedli
elev
ddimer
may
benefit
anticoagul
therapi
futur
studi
use
larg
sampl
size
need
confirm
effect
heparin
manag
patient
recent
studi
demonstr
interact
spike
protein
receptor
bind
domain
rbd
heparin
suggest
develop
heparinbas
therapeut
microftwest
et
al
great
interest
develop
novel
heparinbas
compound
vitamin
c
pleiotrop
role
modul
immun
system
carr
maggini
known
antioxid
properti
antioxid
gener
accept
adjuv
therapi
critic
ill
patient
whose
vitamin
c
level
markedli
decreas
carr
et
al
nakano
suzuki
vitamin
c
exert
posit
effect
immun
system
stimul
ifn
product
support
lymphocyt
prolifer
boost
neutrophil
phagocyt
capabl
fig
may
harrison
oudemansvan
straaten
et
al
wilson
acut
lung
injuri
ard
excess
neutrophil
accumul
inflammatori
loci
result
lung
tissu
damag
releas
necrot
cell
content
known
neutrophil
extracellular
trap
papayannopoulo
weiss
vitamin
c
report
prevent
process
moham
et
al
anim
model
sepsi
vitamin
c
shown
protect
lung
barrier
function
reduc
lung
vascular
injuri
diminish
inflammatori
respons
coagul
chang
fisher
et
al
fisher
et
al
phase
trial
patient
critic
sever
sepsi
report
high
dose
vitamin
c
reduc
extent
multipl
organ
failur
mitig
circul
injuri
biomark
level
fowler
et
al
placebocontrol
trial
shown
vitamin
c
could
reduc
durat
cold
chalker
given
patient
frequent
present
lung
damag
vitamin
c
could
promis
candid
tabl
vitamin
known
modul
innat
adapt
immun
system
defici
associ
increas
autoimmun
well
increas
suscept
infect
aranow
grant
et
al
point
role
vitamin
reduc
risk
respiratori
tract
infect
action
mechan
vitamin
includ
induct
antimicrobi
peptid
ie
cathelicidin
defensin
reduc
viral
replic
rate
imped
proinflammatori
cytokin
sever
clinic
trial
vitamin
patient
ie
underway
nonsteroid
antiinflammatori
drug
nsaid
includ
ibuprofen
wide
use
treat
fever
pain
march
report
hypothesi
ibuprofen
increas
risk
develop
sever
fatal
sinc
ibuprofen
known
upregul
receptor
howev
evid
indic
ibuprofen
worsen
clinic
symptom
infect
patient
fitzgerald
kakodkar
et
al
march
us
fda
announc
awar
evid
nsaid
ibuprofen
could
worsen
specif
vaccin
current
avail
contain
infect
meet
urgent
need
effect
vaccin
context
activ
transmiss
compani
institut
worldwid
work
vaccin
variou
approach
result
seri
vaccin
candid
routley
one
promis
one
develop
nation
institut
allergi
infecti
diseas
scientist
togeth
biotechnolog
compani
moderna
fig
moderna
nih
mrna
vaccin
embed
lipid
nanoparticl
encod
viral
protein
deliv
antigen
human
cell
elicit
neutral
antibodi
potent
immun
respons
therebi
protect
healthi
individu
infect
fig
mrna
vaccin
superior
convent
vaccin
given
high
potenc
short
product
cycl
safeti
lack
actual
viral
genom
ahn
et
al
phase
openlabel
doserang
trial
conduct
healthi
adult
volunt
age
year
three
differ
dose
assess
efficaci
appropri
effect
dose
tabl
april
moderna
receiv
award
us
govern
agenc
brada
million
acceler
develop
moderna
first
vaccin
test
clinic
trial
follow
close
anoth
promis
candid
call
jointli
develop
tianjinbas
biotechnolog
compani
cansino
institut
biotechnolog
academi
militari
medic
scienc
develop
cansino
adenovirusbas
viral
vector
vaccin
technolog
platform
use
replicationdefect
adenoviru
type
vector
load
gene
fragment
onto
express
protein
fig
accord
cansino
preclin
data
anim
model
demonstr
elicit
robust
immun
respons
favor
safeti
profil
mak
current
phase
clinic
trial
evalu
safeti
efficaci
initi
wuhan
tabl
recent
publish
studi
lancet
introduc
newli
develop
potenti
effect
vaccin
name
pittcovacc
short
pittsburgh
coronaviru
vaccin
develop
univers
pittsburgh
school
medicin
scientist
pittcovacc
use
sprotein
fragment
stimul
gener
specif
antibodi
fig
pittcovacc
deliv
novel
techniqu
known
microneedl
array
fingertips
patch
tini
needl
strategi
elicit
potent
immun
respons
convent
subcutan
needl
inject
demonstr
suffici
safe
pittcovacc
test
immunogen
mice
emerg
substanti
antibodi
within
week
prime
immun
research
team
hope
test
pittcovacc
human
clinic
trial
next
month
tabl
sciencedaili
usbas
compani
novavax
identifi
vaccin
candid
stabl
prefus
protein
develop
advanc
nanoparticl
technolog
tabl
fig
matrixm
adjuv
incorpor
enhanc
immun
respons
stimul
increas
level
neutral
antibodi
novavax
firstinhuman
trial
start
may
type
vaccin
eg
dna
rna
vector
wholecel
kill
liveattenu
vaccin
rapid
develop
process
routley
phase
studi
novel
dna
vaccin
underway
inovio
despit
serious
pandem
ravag
world
research
take
time
assess
safeti
efficaci
vaccin
anim
model
conduct
relat
human
clinic
trial
prevent
harm
good
occur
hastili
produc
vaccin
zinc
trace
miner
necessari
immun
system
sinc
zincdefici
patient
sever
immun
dysfunct
prasad
interestingli
numer
report
show
loss
sens
smell
tast
earli
stage
infect
peopl
keyhan
et
al
lechien
et
al
well
known
zinc
defici
associ
loss
tast
zinc
supplement
benefici
effect
subject
loss
tast
doti
heyneman
yagi
et
al
collect
like
zinc
defici
patient
infect
may
associ
loss
smell
tast
patient
importantli
zinc
potent
inhibitor
variou
rna
virus
sarscov
te
velthui
et
al
given
inhibit
action
zinc
replic
coronaviru
possibl
zinc
may
benefici
effect
infect
sinc
zinc
supplement
avail
world
first
clinic
trial
intraven
zinc
patient
underway
australia
furthermor
sever
clinic
trial
combin
zinc
candid
ie
hcq
vitamin
vitamin
c
patient
underway
find
recent
vitro
studi
australian
research
notabl
found
ivermectin
antiparasit
drug
could
effect
block
growth
cell
cultur
within
h
even
singl
dose
fig
howev
mechan
though
ivernectin
exert
antivir
action
unknown
studi
demonstr
effect
ivernectin
control
vitro
cali
et
al
studi
efficaci
safeti
inhibit
human
anim
need
investig
pandem
unpreced
crisi
public
health
world
economi
huge
impact
china
countri
fight
unit
understand
benefit
one
benefit
wherea
harm
one
harm
scientist
worldwid
struggl
seek
efficaci
treatment
learn
previou
experi
cope
sar
mer
seri
exist
drug
use
clinic
practic
treat
infect
clinic
trial
evalu
efficaci
safeti
ongo
given
uniqu
viral
structur
distinct
pathogenesi
urgent
need
novel
therapi
includ
vaccin
antivir
discuss
mani
differ
candid
infect
patient
part
patient
infect
medic
drug
ill
therefor
potenti
drugdrug
interact
consid
combin
research
team
china
singapor
unit
state
publish
new
studi
preprint
websit
biorxiv
anderson
et
al
systemat
comprehens
screen
gene
bat
cell
team
identifi
gene
indispens
viral
replic
bat
human
cell
found
carolacton
host
protein
inhibitor
could
effect
inhibit
replic
sever
rna
virus
includ
suggest
carolacton
natur
bacteriaderiv
product
could
novel
therapeut
drug
final
understand
mechan
human
could
help
develop
novel
therapeut
drug
must
protect
infect
aforement
candid
approv
jz
bx
perform
studi
design
data
collect
data
analysi
data
interpret
write
kh
perform
studi
design
data
interpret
write
author
approv
final
manuscript
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
